Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)
Key features and details
- Cell permeable, irreversible pan-caspase inhibitor
- CAS Number: 187389-52-2
- Soluble in DMSO to 20 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor -
Description
Cell permeable, irreversible pan-caspase inhibitor -
Alternative names
- Z-VAD-FMK (cell permeable)
-
Biological description
A cell-permeable, irreversible, pan-caspase inhibitor. Inhibits caspase processing and apoptosis induction in tumor cells in vitro. Once in the cell, endogenous esterase activity hydrolyzes the methyl groups to form the biologically active form. Therefore, when using with isolated, purified or recombinant caspase enzymes, pre-treatment with an esterase is required.
-
CAS Number
187389-52-2 -
Chemical structure
Properties
-
Molecular weight
467.49 -
Molecular formula
C22H30FN3O7 -
Sequence
VAD (Modifications: N-terminal benzyloxycarbonyl; C-terminal FMK; Asp-3 = Asp(OMe)) -
PubChem identifier
5497173 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 20 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
FCC(=O)C(CC(=O)OC)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C -
Source
Synthetic
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120487 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Images
-
Chemical Structure - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)2D chemical structure image of ab120487, Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor
-
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)HeLa cells were incubated at 37°C for 1h with vehicle control (0 µM) and different concentrations of Z-VAD(OMe)-FMK (ab120487). After this incubation 10 µM of camptothecin (ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLA cells correlates with an increase in Z-VAD(OMe)-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 µg /ml and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution.
-
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)Titration of the Caspase inhibitor Z-VAD(OMe)-FMK (ab120487) (duplicates; +/- SD). -
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (14)
ab120487 has been referenced in 14 publications.
- Gain C et al. Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway. PLoS Pathog 16:e1008105 (2020). PubMed: 32092124
- Hoffmann S et al. FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease. EMBO Rep 21:e50662 (2020). PubMed: 32776417
- Mei S et al. Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors. Mol Cell Proteomics 19:1236-1247 (2020). PubMed: 32357974
- Mahalapbutr P et al. Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations. Cancers (Basel) 11:N/A (2019). PubMed: 30925736
- Pavlyukov MS et al. Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors. Cancer Cell 34:119-135.e10 (2018). PubMed: 29937354
